November 8, 2018
ipeline rapidly advancing with three clinical trials planned to initiate by early 2019, including a SPR994 Phase 3 initiation around year-end 2018 CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections, today announced financial results for the...
2018 scale-up of Biom’up’s manufacturing facility near Lyon (France) completed, allowing for a larger throughput and increased shipments of devices to the US and EU markets • Six key manufacturing processes upgraded, thoroughly reviewed and approved by the FDA and EMA; a strong validation of the Company capability to efficiently execute a comprehensive and demanding...
The Lundbeck Foundation is yet again to be found at the very top of the foundation transparency barometer. A principal shareholder in large companies and distributor of considerable funding has a great responsibility to tell the world openly and honestly what it does, and how it does it. This is the philosophy behind the Lundbeck...


Lundbeck Foundation to cover universities’ indirect costs
10. December 2018
Apply for a Professorship!
5. December 2018
New analytical method exposes the body’s policemen
19. November 2018


Lundbeckfonden Ventures

Lundbeckfonden Emerge